Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine vs Temozolomide in Combination With Radiotherapy in Patients With IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
J. Clin. Oncol 2024 Oct 02;[EPub Ahead of Print], SEO Kacimi, C Dehais, L Feuvret, O Chinot, C Carpentier, C Bronnimann, E Vauleon, A Djelad, E Cohen-Jonathan Moyal, O Langlois, M Campone, M Ducloie, G Noel, S Cuzzubbo, L Taillandier, C Ramirez, N Younan, P Menei, F Dhermain, C Desenclos, F Ghiringhelli, V Bourg, D Ricard, T Faillot, R Appay, E Tabouret, L Nichelli, B Mathon, A Thomas, S Tran, F Bielle, A Alentorn, JB Iorgulescu, PY Boëlle, K Labreche, K Hoang-Xuan, M Sanson, A Idbaih, D Figarella-Branger, F Ducray, M TouatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.